Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida.
Clin Gastroenterol Hepatol. 2013 Dec;11(12):1562-70.e1-2. doi: 10.1016/j.cgh.2013.06.017. Epub 2013 Jul 12.
BACKGROUND & AIMS: US guidelines recommend surveillance of patients with Barrett's esophagus (BE) to detect dysplasia. BE conventionally is monitored via white-light endoscopy (WLE) and a collection of random biopsy specimens. However, this approach does not definitively or consistently detect areas of dysplasia. Advanced imaging technologies can increase the detection of dysplasia and cancer. We investigated whether these imaging technologies can increase the diagnostic yield for the detection of neoplasia in patients with BE, compared with WLE and analysis of random biopsy specimens.
We performed a systematic review, using Medline and Embase, to identify relevant peer-review studies. Fourteen studies were included in the final analysis, with a total of 843 patients. Our metameter (estimate) of interest was the paired-risk difference (RD), defined as the difference in yield of the detection of dysplasia or cancer using advanced imaging vs WLE. The estimated paired-RD and 95% confidence interval (CI) were obtained using random-effects models. Heterogeneity was assessed by means of the Q statistic and the I(2) statistic. An exploratory meta-regression was performed to look for associations between the metameter and potential confounders or modifiers.
Overall, advanced imaging techniques increased the diagnostic yield for detection of dysplasia or cancer by 34% (95% CI, 20%-56%; P < .0001). A subgroup analysis showed that virtual chromoendoscopy significantly increased the diagnostic yield (RD, 0.34; 95% CI, 0.14-0.56; P < .0001). The RD for chromoendoscopy was 0.35 (95% CI, 0.13-0.56; P = .0001). There was no significant difference between virtual chromoendoscopy and chromoendoscopy, based on Student t test analysis (P = .45).
Based on a meta-analysis, advanced imaging techniques such as chromoendoscopy or virtual chromoendoscopy significantly increase the diagnostic yield for identification of dysplasia or cancer in patients with BE.
美国指南建议对巴雷特食管(BE)患者进行监测以检测异型增生。BE 通常通过白光内镜(WLE)和随机活检标本进行监测。然而,这种方法并不能明确或一致地检测出异型增生区域。先进的成像技术可以提高异型增生和癌症的检出率。我们研究了这些成像技术是否可以与 WLE 和随机活检标本分析相比,提高 BE 患者中肿瘤的检出率。
我们使用 Medline 和 Embase 进行了系统评价,以确定相关的同行评审研究。最终分析纳入了 14 项研究,共 843 名患者。我们感兴趣的 metameter(估计值)是使用先进的成像技术与 WLE 相比,检测异型增生或癌症的检出率的差异,定义为配对风险差异(RD)。使用随机效应模型获得估计的配对 RD 和 95%置信区间(CI)。通过 Q 统计量和 I(2)统计量评估异质性。进行了探索性的 meta 回归,以寻找 metameter 与潜在混杂因素或修饰因素之间的关联。
总体而言,先进的成像技术使异型增生或癌症的检出率提高了 34%(95%CI,20%-56%;P <.0001)。亚组分析表明,虚拟 chromoendoscopy 显著提高了诊断率(RD,0.34;95%CI,0.14-0.56;P <.0001)。chromoendoscopy 的 RD 为 0.35(95%CI,0.13-0.56;P =.0001)。根据学生 t 检验分析,虚拟 chromoendoscopy 和 chromoendoscopy 之间没有显著差异(P =.45)。
基于荟萃分析,chromoendoscopy 或虚拟 chromoendoscopy 等先进的成像技术可显著提高 BE 患者异型增生或癌症的检出率。